AFREZZA is the New and Improved Inhalable Insulin for Diabetes
Coming soon to a pharmacy near you: AFREZZA, a new fast-acting form of inhaled insulin. According to recent studies, AFREZZA , will provide "glycemic control similar to standard insulin treatments with less risk of hypoglycemia and weight gain." Still waiting for FDA approval, it also appears that AFREZZA will have a lower risk of causing lung problems than Exubera, the first inhalable insulin on the market.
"AFREZZA is an ultra-rapid-acting insulin, and clinical studies have shown us that it has the potential to change diabetes therapy, because in the body, AFREZZA looks like the insulin that's normally in a person's body," said Andrea Leone-Bay, vice president of pharmaceutical development for MannKind Corp., manufacturer of AFREZZA.
It is intended for use at mealtimes to control rapid rises in blood sugar that occur after meals in people with diabetes. The idea of an inhaled insulin appeals to diabetics who must use insulin every time they eat.
For information on diabetes supplies or insulin pumps, click here!
